MMM · Medicare/Medicaid
H.R. 3514/S. 1816: Improving Seniors' Timely Access to Care Act of 2025 - requires Medicare Advantage plans to implement electronic prior authorization, increase transparency, protect enrollees, and adhere to new response timeframes to improve timely access to care. S. 1640/H.R. 879: Medicare Patient Access and Practice Stabilization Act of 2025 - This bill increases certain payment adjustments under the Medicare physician fee schedule for services furnished between April 1, 2025, and January 1, 2026. S. 1460/H.R. 786: Preserving Patient Access to Accountable Care Act - extends Medicare incentive payments for alternative payment models to 2027, with a new rate of 3.53 percent, to promote continued participation and improve healthcare efficiency. H.R. 4206/S. 1261: CONNECT for Health Act - expands access to telehealth services under Medicare H.R. 2433: Reducing Medically Unnecessary Delays in Care Act - mandates that prior authorization decisions under Medicare be made by qualified physicians, based on medical necessity and evidence-based standards, with transparency and input from practicing physicians. H.R. 1509/S. 752: Accelerating Kids Access to Care Act - To amend titles XIX and XXI of the Social Security Act to streamline the enrollment process for eligible out-of-state providers under Medicaid and CHIP. H.R. 2484: Seniors' Access to Critical Medications Act of 2025 - establishes an exception to the physician self-referral prohibition for certain outpatient drugs under Medicare, mandates a study on drug dispensing practices, and reduces the Medicare improvement fund by $18 million. H.R. 2120/S. 1031: ROCR Value Based Program Act - establishes a new payment program for radiation oncology services, focusing on stable payments, quality care, and patient access, while exempting it from budget neutrality adjustments. H.R. 4559: Prompt and Fair Pay Act - to establish payment parity between Medicare Advantage and fee-for-service Medicare, and to establish prompt payment requirements under Medicare Advantage. H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act - provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation. H.R. 5081/S. 2709: Telehealth Modernization Act - to extend certain telehealth flexibilities under the Medicare program. H.R. 4752/S. 2760: Reducing Hereditary Cancer Act - to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation.
Literal federal measure citations: H.R. 3514, S. 1816, S. 1640, H.R. 879, S. 1460, H.R. 786, H.R. 4206, S. 1261, H.R. 2433, H.R. 1509, S. 752, H.R. 2484, H.R. 2120, S. 1031, H.R. 4559, H.R. 4299, H.R. 5081, S. 2709, H.R. 4752, S. 2760
HCR · Health Issues
H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles and copays, for prescription drugs, with changes effective for plan years beginning January 1, 2026. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 1262/S. 932: Mikaela Naylon Give Kids a Chance Act of 2025 - To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes. HR 929/S.266: Dr. Lorna Breen Health Care Provider Protection Reauthorization Act - To reauthorize the Dr. Lorna Breen Health Care Provider Protection Act, and for other purposes. H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses.
Literal federal measure citations: H.R. 6423, S. 864, S. 526, H.R. 1262, S. 932, HR 929, S.266, H.R. 4191, S. 1784, H.R. 3955, S.2062, S. 1954, H.R. 4101, H.R. 3521, S. 705, H.R. 5509, S. 2903, H.R. 4425, S. 2287
BUD · Budget/Appropriations
FY 2026 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Peer Reviewed Cancer Research Program (PRCRP). FY 2027 Appropriations for the National Institutes of Health (NIH), National Cancer Institute (NCI), the Food & Drug Administration (FDA), the Advanced Research Projects Agency for Health (ARPA-H), the Centers for Disease Control and Prevention (CDC), and the Department of Defense's Peer Reviewed Cancer Research Program (PRCRP).
